JKS enters the final days of May in an unusual position: short sellers are beating a hasty retreat even as the company's largest insider was selling into the strength.
Short interest has dropped sharply — down 27% over the week to 3.0% of the free float, the lowest level in at least six weeks. That unwind accelerated in the second half of the week, with shares short falling from roughly 2.1 million to under 1.6 million in just three sessions. The borrow market tells the same story: availability is wide open at 509%, meaning there are around five shares available to lend for every one already borrowed, and the cost to borrow has drifted back toward 0.44% after a monthly peak above 0.68% in early May. Neither metric suggests any meaningful squeeze pressure. This is a measured, orderly exit by shorts, not a forced unwind.
Options positioning has quietly become more defensive. The put/call ratio climbed to 0.90 this week, well above its 20-day average of 0.80 — a move roughly 1.2 standard deviations above the norm. That's not extreme on its own, but the direction is clear: put demand has been rising steadily since early May, when the PCR was sitting closer to 0.70. The 52-week range runs from 0.37 to 1.72, so there's room for significantly more hedging, but the recent drift upward is worth noting against a backdrop of short covering.
The Street's view on JKS is cautious but not catastrophically bearish. UBS raised its price target this week to $24 from $23 while holding its Neutral rating — a marginal upgrade that essentially prices the stock where it is now at $23.31. Goldman Sachs, which has maintained a Sell for over a year, last raised its target to $20 in late 2025. The mean analyst target is $31, though that figure is lifted by a Daiwa Capital Buy initiated in March at $28.50 — the only bullish voice in the recent record. The fundamental backdrop explains the hesitation: the company carries net debt of around $2.7 billion, reported an estimated net loss of $173 million on $10.6 billion in revenue, and trades at a price-to-book of just 0.37. EV/EBITDA is roughly 6-8x depending on the source, which is cheap on paper, but only if margins recover. EPS momentum ranks in the bottom decile — 8th percentile over 30 days and 1st percentile over 90 days — signalling the earnings revision trend has been relentlessly negative.
The insider picture complicates the short-covering narrative. On May 13, co-founder and director Li Xianhua sold 1.28 million shares at roughly $6.38 per share — a transaction that appears priced at a significant discount to the current $23 market price, which likely reflects the ADR-to-H-share conversion structure. Separately, independent directors sold small tranches on the same date. The net 90-day insider flow is a positive $8.3 million in nominal value, but that is entirely explained by the large equity award grants distributed on May 1 to the CEO, founder, and CFO — standard compensation, not open-market conviction buying. In context, the only voluntary insider transactions this month were sales.
Peer context reinforces the caution. CSIQ gained about 5% on the week but fell over 6% on Friday. Chinese-listed solar peers across the SHSE and SZSE broadly dropped 5-9% on the day, suggesting sector-wide selling pressure that JKS largely sidestepped with its 2% weekly gain. The stock's relative resilience, combined with rapid short covering, points to a market that briefly re-rated the name higher — though with the next earnings event not until August 14, the next hard data point is still more than ten weeks away.
The question worth tracking is whether the short unwind is a genuine re-rating or simply a mechanical reversal of the position that built in mid-May — and whether the put/call drift and executive selling offer an early answer.
See the live data behind this article on ORTEX.
Open JKS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
